Biogen hits the gas pedal on Aduhelm confirmatory trial, hoping to deliver results in 2026

Biogen is looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s disease drug Aduhelm out in four years, as the fate of this drug, and Biogen itself, rests in the balance.